About Scholar Rock
Scholar Rock is a company based in Cambridge (United States) founded in 2012. Scholar Rock has raised $103.3 million across 4 funding rounds from investors including Fidelity Investments, Arch Venture Partners and Invus. The company has 196 employees as of December 31, 2024. Scholar Rock offers products and services including Therapies for Spinal Muscular Atrophy and Therapies for Cancer. Scholar Rock operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
- Headquarter Cambridge, United States
- Employees 196 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Scholar Rock Holding Corporation
-
Annual Revenue
Not available
-
Net Profit
-$246.29 M (USD)-48.56as on Dec 31, 2024
-
EBITDA
-$250.12 M (USD)-48.48as on Dec 31, 2024
-
Total Equity Funding
$103.3 M (USD)
in 4 rounds
-
Latest Funding Round
$205 M (USD), Post-IPO
Jun 17, 2022
-
Investors
Fidelity Investments
& 7 more
-
Employee Count
196
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Scholar Rock
Scholar Rock is a publicly listed company on the NASDAQ with ticker symbol SRRK in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Scholar Rock
Scholar Rock offers a comprehensive portfolio of products and services, including Therapies for Spinal Muscular Atrophy and Therapies for Cancer.
Investigational treatments targeting growth factors for SMA
Drugs for solid tumors via selective protein inhibition
People of Scholar Rock
Unlock access to complete
Unlock access to complete
Funding Insights of Scholar Rock
Scholar Rock has successfully raised a total of $103.3M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $205 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Scholar Rock
Scholar Rock has secured backing from 8 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Fidelity Investments, Arch Venture Partners and Invus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Long-term private equity investments in transformational opportunities are pursued.
|
Locked | Locked | Locked | |
|
US focused venture capital firm
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked |
Investor details for Scholar Rock
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Scholar Rock
Investment portfolio details for Scholar Rock
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Scholar Rock
Detailed financials for Scholar Rock
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Scholar Rock Comparisons
Peer comparison for Scholar Rock
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Scholar Rock
Scholar Rock operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Drugs for CNS disorders are developed and advanced.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
Detailed competitors of Scholar Rock
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Scholar Rock
Complete news archive for Scholar Rock
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Scholar Rock
Scholar Rock was founded in 2012 and raised its 1st funding round 2 years after it was founded.
Scholar Rock is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Nagesh Mahanthappa is the current CEO of Scholar Rock.
Scholar Rock is a funded company, having raised a total of $103.3M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Scholar Rock is 196.
Scholar Rock was founded in 2012 in Cambridge, United States, within the biotechnology sector. Niche modulators, a class of biologic therapies, are discovered and developed to selectively target dysregulated growth factors in disease microenvironments, particularly members of the TGFβ superfamily. These therapies address conditions such as fibrosis, musculoskeletal disorders, and autoimmune diseases. Operations focus on antibody-based inhibitors like SRK-015, a monoclonal antibody for latent myostatin activation in primary myopathies.
Scholar Rock's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Biohaven Pharmaceutical.
Scholar Rock offers Therapies for Spinal Muscular Atrophy and Therapies for Cancer.
Yes, Scholar Rock is publicly traded on NASDAQ under the ticker symbol SRRK.
Scholar Rock has 8 investors. Key investors include Fidelity Investments, Arch Venture Partners, Invus, Redmile Group, and Polaris Partners.
The ticker symbol of Scholar Rock is SRRK on NASDAQ.